7 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Matthew Galsky: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer Enfortumab vedotin, Pembrolizumab - Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | Matthew Galsky | 75 | 2025-04-07 | 2026-08-05 |
| Pembrolizumab in Muscle-invasive Bladder Cancer Pembrolizumab - Muscle Invasive Bladder Carcinoma, Localized Cancer | Phase 2 | Active not recruiting | Matthew Galsky | 46 | 2022-07-13 | 2026-04-08 |
| Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer Atezolizumab, PGV001, Poly ICLC - Urothelial/Bladder Cancer, Nos | Phase 1 | Completed | Matthew Galsky | 10 | 2019-05-08 | 2023-05-16 |
| Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer Tremelimumab - Urothelial Carcinoma | Phase 2 | Completed | Matthew Galsky | 26 | 2018-11-12 | 2024-07-03 |
| Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing Nivolumab, Gemcitabine, Cisplatin - Bladder Cancer | Phase 2 | Completed | Matthew Galsky | 76 | 2018-07-13 | 2024-06-27 |
| Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer Nivolumab, Gemcitabine, Carboplatin - Metastatic Urothelial Cancer | Phase 2 | Completed | Matthew Galsky | 49 | 2018-05-10 | 2024-05-16 |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Olaparib - Metastatic Urothelial Cancer | Phase 2 | Completed | Matthew Galsky | 19 | 2018-04-17 | 2023-11-22 |
| Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Placebo, Pembrolizumab - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Matthew Galsky | 108 | 2015-11-11 | 2022-09-30 |
| Metformin for Rising PSA Remote Trial Metformin - Prostate Cancer | Not applicable | Completed | Matthew Galsky | 15 | 2014-07-01 | 2017-12-22 |
| Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors Cisplatin, Carboplatin - Solid Tumors, Bladder Cancer | Phase 1 | Terminated | Matthew Galsky | 14 | 2012-01-01 | 2013-11-27 |
| Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Amrubicin - Bladder Cancer | Phase 2 | Terminated | Matthew Galsky | 22 | 2011-02-01 | 2018-04-23 |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma Everolimus, Paclitaxel - Transitional Cell Carcinoma, Bladder Carcinoma | Phase 2 | Terminated | Matthew Galsky | 36 | 2010-12-01 | 2023-11-24 |
Urinary Bladder Neoplasms (5) · Carcinoma, Transitional Cell (4) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Urologic Neoplasms (1)
pembrolizumab (3) · Carboplatin (2) · Cisplatin (2) · Gemcitabine (2) · Nivolumab (2) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · Everolimus (1) · Metformin (1) · Oxaliplatin (1) · Paclitaxel (1) · Saline Solution (1) · amrubicin (1) · atezolizumab (1) · enfortumab vedotin (1) · olaparib (1)
United States (12)
Matthew D Galsky, MD (3) · Matthew D. Galsky, M.D. (1)
PMID 30657386, PMID 32271672, PMID 35438782, PMID 37783966, PMID 38180804, PMID 40346292